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ABSTRACT 
 
Human Immunodeficiency Virus (HIV) has become a global pandemic with at least 25 million 
deaths and no cure. One of the most important targets to inhibit this virus is HIV-1 protease 
(PR), which is required to cleave the viral proteins needed for maturation of the virus after it 
invades and replicates in the host cell. There are nine protease inhibitors that are used in AIDS 
treatment.  The virus loses susceptibility to these inhibitors by drug resistance due to mutations. 
The goal of the project is to examine the highly drug resistant HIV PR P51 in its complex with 
inhibitors.  In this experiment we expressed and purified HIV PR P51 protein. We performed 
protein crystallization with inhibitors Tipranavir, Amprenavir, Darunavir, and Saquinavir to 
obtain the structure of the protease and the inhibitors in their complexes. Future analysis of the 
crystal structures will help with the development of successful therapeutic inhibitors.  
 
INDEX WORDS:  Human Immunodeficiency Virus, Inhibitor, Mutant, Protease P51, Drug 
Resistance, Protein Crystallization 
  
 
 
 
 
 
 HIV-1 PR P51 MUTANT COMPLEX FORMATION WITH INHIBITORS 
 
by 
 
Shaquita T. Greene 
 
An Honors Thesis Submitted in Partial Fulfillment of the Requirements for the Degree of 
Bachelor of Science 
in the College of Arts and Sciences 
Georgia State University 
 
 
 
2012 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Copyright by 
Shaquita Tashon Greene 
2012 
 HIV-1 PR P51 MUTANT COMPLEX FORMATION WITH INHIBITORS 
 
by 
Shaquita T. Greene 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Honors Thesis Director: Dr. Irene Weber 
Honors College Associate Dean: Dr. Sarah Cook 
 
 
 
Electronic Version Approved: 
 
GSU Honors College 
Georgia State University 
December 2012 
 
 
v 
Dedication 
I would like to dedicate this paper to my family and all those who have supported me along the 
way. I greatly appreciate you all and I love you very much. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
vi 
Acknowledgements 
 
I would like to acknowledge those who have helped me with my research and have helped to edit 
this paper, Dr. Irene Weber and Ying Zhang. I really appreciate your help and I have enjoyed 
working with the both of you. I also would like to thank Dr. Johnny (Johnson) Agniswamy. 
Thank you all so much for your help. I greatly appreciate everything you have done for me. 
 
  
vii 
Table of Contents 
Dedication page v 
Acknowledgements page vi 
List of Tables page viii 
List of Figures page ix 
Introduction page 1 
        Human Immunodeficiency Virus page 3 
        HIV-1 Virion Structure page 5 
        HIV Protease page 7 
        Drug Resistance page 7 
Experimental Methods page 11 
       Protein Expression page 11 
       Protein Purification page 12 
       Protein Crystallization page 13 
       Measurement of Protease Activity and                                         
Inhibition 
page 13 
Results page 14 
      Expression of HIV Protease P51 Mutant page 14 
      Purification of HIV Protease Mutant P51 page 14 
      Crystallization of HIV Protease P51 Mutant  
      with Inhibitors 
page 14 
      Enzyme activity and inhibition page 15 
Discussion page 16 
 
 
 
  
viii 
LIST OF TABLES 
Table 1: HIV-1 Protease Inhibitors and the Related Drug Resistance Mutations   page 8 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ix 
LIST OF FIGURES 
Figure 1: HIV-1 protease and Gag and Gag-Pol with cleavage sites                           page 2 
Figure 2: HIV-1 Life Cycle in Host Cell                   page 4 
Figure 3: HIV-1 structure and structural proteins                  page 6 
Figure 4: Structure of HIV-1 protease in dimer form                             page 9 
Figure 5: Crystal Structure of HIV-1 PR Dimer with Sites of Drug Mutation              page 9 
Figure 6: Molecular Structure of SQV, APV, DRV, and TPV                                         page 11 
Figure 7: HIV-1 PR p51 Gel Filtration Results                                                                    page 17 
Figure 8: PR p51 with APV crystals                  page 18 
Figure 9: PR p51 with DRV crystals                  page 18 
Figure 10: PR p51 with SQV crystals                            page 19 
Figure 11: PR p51 with TPV crystals                                                                         page 19  
 
 
 
 
 
 
 
 
1 
Introduction 
The number of people currently living with Human Immunodeficiency Virus (HIV) has 
increased drastically since the virus was first recognized (4).  UNAIDS (Joint United Nations 
Programme on HIV/AIDS), WHO (World Health Organization), and UNICEF (United Nations 
Children’s Fund) have estimated at least 30.6 million adults and 3.4 million children who are 
infected with HIV at the end of the year of 2012 (17). The development of Highly Active 
Antiretroviral Therapy (HAART) using a combination of different antiviral drugs to suppress 
HIV over the years has helped to reduce the effects of the disease on the immune system but still 
there is no cure (2). Even with the drug therapies available today, multidrug resistance is 
becoming more of an issue. HIV protease (PR) is an enzyme that is vital to the functioning of 
HIV (6). PR’s catalytic role is an important step in HIV replication because it generates mature 
infectious viral particles by cleaving viral polyproteins Gag and Gag-Pol (Figure 1) (6). Gag is 
cleaved into three large protein’s called p24, p17, p7 and small proteins called p6, p2, and p1 
(6).The large proteins contribute to the structure of the virion and RNA packing and the function 
of the small proteins are uncertain (6). Gag- pol is cleaved into protease (PR), reverse 
transcriptase (RT), and integrase (IN) (6). Consequently, HIV protease has been a valuable 
therapeutic target for HIV/AIDS structure-based drug design for decades (16). 
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Figure 1. This figure shows the HIV-1 protease at a 180 degree angle (B) and gag and gag-pol 
genes that are cleaved by HIV-1 protease and at what site these proteins are cleaved (C). [6] 
Figure 1. HIV-1 protease and Gag and Gag-Pol with cleavage sites. 
3 
Human Immunodeficiency Virus  
Human Immunodeficiency Virus (HIV) is an enveloped retrovirus that leads to the 
development of Autoimmune Deficiency Syndrome (AIDS) (16). HIV-1 virus can damage the 
immune system by depleting the CD4+ T cells, also known as T helper cells (13). In order for 
HIV to successfully destroy the T helper cells, it must first invade the body successfully and 
undergoes replication. HIV’s mode of transmission is through sexual, percutaneous, and 
perinatal methods but the most common method is sexual contact (9). Some examples of 
behaviors that can cause the viral infection come from contact with bodily fluids are sharing of 
needles, syringes, and being born to an infected mother (9). Once it has entered the bloodstream 
it can begin its phase of replication and destruction of T helper cells. HIV binds to the CD4 and 
CXCR5 receptors and fuses its envelope with the host cell cellular membrane and liberates its 
envelope. After that, the proteins and nucleic acids that compose the virus are allowed to enter 
into the cytoplasm of the cell (8). Then, the ribonucleic acid (RNA) is reverse transcribed into 
double stranded deoxyribonucleic acid (DNA). The DNA is then integrated into the host DNA 
via viral integrase (8). The DNA is transcribed into new viral RNA and new viral proteins are 
made. The proteins with the RNA assemble around the host membrane to bud forming the 
mature viral particle (8). The new viral particle then continuously invades the host cells and 
multiplies, taking over the host cell machinery (Figure 2). 
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Figure 2. HIV-1 Life Cycle in Host Cell. 
Figure 2. Representation of HIV-1 virus life cycle in the host cell. Positive (+) and negative (-) cellular 
factors are indicated next to the step in viral replication that they affect. (13) 
5 
HIV-1 Virion Structure 
The HIV-1 virion shown in Figure 3 (15) is a spherical and compact structure. The viral 
envelope is the outmost part which is a plasma membrane of host-cell origin. On this membrane 
is the envelope which includes the surface unit glycoprotein (SU) gp120 and transmembrane 
envelope (TM) gp41. The viral structure proteins are referred to as Gag proteins: the matrix 
protein (MA) is located under the envelope and encases the capsid shell; two copies of genomic 
single-stranded RNA are enclosed by the conical capsid which comprising of capsid protein 
(CA); the single-strand RNA is tightly bound to the nucleocapsid proteins (NC) (5). Associated 
with the NC and RNA within the capsid are the Pol gene encoded viral-specific enzymes 
including the protease (PR), RNA polymerase (RT), integrase (IN) and RNase H (RH). The virus 
particles also package the accessory proteins, Nef, Vif, and Vpr while the other three additional 
accessory proteins Rev, Tat and Vpu which function in the host cell do not appear in the virions 
(15). 
 
 
 
 
 
 
 
 
 
 
6 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. HIV-1 structure and structural proteins. 
 
Figure 3. This represents the HIV-1 virion structure and the structural proteins. The 
structural protein include Surface unit glycoprotein (SU)gp120, transmembrane 
envelope (TM) gp41, the matrix protein (MA) capsid protein (CA), nucleocapsid 
proteins (NC), protease (PR), RNA polymerase (RT), integrase (IN) and RNase H 
(RH), accessory proteins ( Nef, Vif, Vpr, Rev, Tat and Vpu). (Turner, et. al) 
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HIV Protease 
Protease is an enzyme that catalyzes the cleavage of peptide bonds between amino acids 
of a protein (6). HIV-1 protease functions by cleaving peptide bonds of HIV-1 viral proteins. 
HIV-1 protease is encoded on the 5’ end of the 99 amino acid HIV-1 gene gag-pol (6). The 
protease cleaves amino acid sequences in the Gag and Gag-Pol polyproteins, which is necessary 
in order for the maturation and replication of virion (6, 8). Lack of an efficient protease causes 
the development of immature, noninfectious viral particles, which is one of the reasons that the 
protease is a target for inhibition with many synthetic inhibitors (6). There are ten inhibitors of 
HIV protease (PR) that are used in antiviral therapy. They are amprenavir (APV), atazanavir, 
indinavir, lopinavir, nelfinavir, ritonavir, nelfinavir, saquinavir (SQV), tipranavir(TPV), and 
darunavir (DRV) (6). A protease inhibitor (PI) is designed to inhibit HIV PR based on its 
structure, mainly its active site (16). These inhibitors interact competitively with the active site 
and the transition state of the enzyme reaction, inactivating the enzyme function. PIs are very 
effective in HAART treatment for AIDS and are usually used in a combination of three different 
antiviral drugs. 
Drug Resistance 
There is currently no cure for the HIV infection, but there are treatments currently 
available to slow the progression of the disease. Creation of therapeutic interventions like 
inhibitors has proven to be successful but have been succeeded by resistance. The creation of 
these antiviral inhibitors was promising due to the knowledge of the crystal structure of HIV 
protease and how it binds substrate like inhibitors. One such inhibitor, darunavir (DRV), which 
is a structure-based designed nonpeptidic ligand (10), has been widely used for the treatment of 
drug-naïve and multidrug-resistant HIV-1 infected patients and was the most recently approved 
8 
PI for drug resistant infections (18-20). Similar to other retroviral polymerases, HIV RT does not 
have a proofreading function and thus increases the mutational rates of the virus. The emergence 
of resistance to HIV-1 PIs is associated with the appearance of amino acid substitution mutations 
in the viral protease gene (Table 1). The mechanism for the development of resistance to PIs is 
quite complicated (5). The locations of PI-resistant mutations vary from substrate/inhibitor 
binding site, dimer interface, and flap region to surface of PR (Figure 4)(1). One explanation is 
that the residues near the active site can directly interfere with the binding of the inhibitor to the 
enzyme by modifying its specificity and/or affinity (20). Another cause for those mutations 
which do not directly change the shape or property of the binding cavity is that they may affect 
the efficiency of catalysis and the stability of the PR, or influence enzyme active site via long-
range structural perturbations (11). To date, among the 99 amino acid residues of the protease, 25 
or more have been implicated in resistance to PIs (Figure 5) (12).  
 
 
 
 
 
 
 
 
 
 
 
Table 1. This table represents known antiviral data for clinical protease inhibitors and their drug 
resistant mutations. Bold red indicates phenotypic evidence for reduced susceptibility in vitro and 
clinical evidence for reduced virological response. Underlined bold red indicates drugs that should 
be contraindicated when the mutation is present. ((http://hivdb.stanford.edu/cgi-bin/PIResiNote.cgi, 
HIV Drug Resistance Database, Stanford University) 
 
 
Table 1. HIV-1 Protease Inhibitors and the Related Drug Resistance Mutations 
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Figure 4. Structure of dimer of HIV-1 protease. Locations of 14 amino acid substitutions in the dimer structure 
and a list of substitutions in HIV PR P51 (Figure provided by Ying Zhang).  
 
Figure 4. Structure of HIV-1 protease in dimer form. 
Figure 5. Shaded regions in monomer indicate the secondary structure of the dimeric enzyme. The 
three mutations Q7K, L33I, and L63I in PR to prevent its intrinsic autoproteolysis and the active site 
aspartic acid residues of each monomer are shown in a stick representation. Positions of drug-resistant 
mutations are indicated in blue. (12) 
 
Figure 5. Crystal Structure of HIV-1 PR Dimer with Sites of Drug Mutation. 
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It has been reported that substitution of a variety of amino acids were related to HIV-1 
resistance to DRV although it has a potent genetic barrier to the development of HIV-1 
resistance and effectively inhibits PR enzymatic activity and dimerization (5). Hence, to further 
design more effective anti-HIV-1 drugs, highly DRV-resistant HIV-1 variants were acquired to 
elucidate the mechanism for development of DRV resistance. In Koh’s lab, in vitro selection of a 
mixture of 8 highly DRV-susceptible HIV-1 clinical isolates  (HIV-1MIX), which contain 9 to 
14 PI-resistant mutations, was conducted to be propagated and thus a series of highly DRV-
resistant viral populations were produced at different passages (10). The population at passage 51 
(HIV-1MIXP51) replicated well at the concentration of 5 μM DRV containing 14 amino acid 
substitutions related to HIV-1 resistance (10). HIV-1MIXP51 has shown a high resistance to 
amprenavir, indinavir, nelfinavir, ritonavir, lopinavir and atazanavir in addition to darunavir (all 
with EC50s > 1 μM) and moderate resistance to saquinavir (33 fold increase in EC50) and 
tipranavir (18 fold increase in EC50) (6). Meanwhile, in the Louis’s lab, they assayed the 
inhibition of protease from HIV-1MIXP51 (P51) and the precursor flanked by the transframe 
region (TRF) to its N-terminus (7). It has also shown that the binding constant KL of DRV for 
PR-P51 was about 7400 fold higher than for wild type protease while the IC50 of TFR- PR-P51 is 
over 150 fold to TFR-PR. Hence, we are trying to study the crystal structures of HIV PR P51 
with DRV, APV, SQV and TPV (molecular structures, Figure 6). Crystallizations of these four 
complexes are performed as the basis for structural study. 
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Experimental Methods and Materials 
Protein Expression 
In order to express the HIV-1 protease mutant P51, a bacterium is used and the gene of 
interest is inserted into the plasmid. In this experiment, E-coli bacteria were used as the 
expression system and pET11A plasmid was used. It contains approximately 5,000-6,000 base 
pairs (bp) and is ampicillin resistant. In order to express the protein, an expression system was 
created. The large broth media was created by adding 25 g of Luria broth (solid) to 1 L of 
distilled water. Mixture was stirred and carbenicillin (CBN) with a final concentration of 100 
µg/ml was added to mixture. 25 ml Luria broth was created and CBN with a final concentration 
Amprenavir 
Figure 6. This image shows the molecular structure of the 4 clinical inhibitors for HIV-1 
protease that were used in this study. 
Figure 6. Molecular Structure of SQV, APV, DRV, and TPV 
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of 100 µg/ml was added to mixture. The cells were inoculated into smaller broth mixture and 
allowed to grow at 37ºC overnight.  After stirring overnight, starter culture was added to larger 
broth 1 L solution and allowed to shake until optical density (OD) value reached approximately 
0.5-0.6. Isopropylthio-β-galactoside (IPTG) with a final concentration of 2mM was added to 
induce protein expression for approximately 3-4 hours. Mixture was then centrifuged at 6,000 
rpm for 20 minutes and pellet was retrieved. Pellet was resuspended twice in 50 ml of TE Buffer 
(50mM Tris and 10mM EDTA in 1L of dH2O) and centrifuged at 6,000 rpm for 20 minutes. 
Pellet was resuspended in a 60 ml of TE solution (TE buffer volume is 20 times ml of the cell 
weight) to prevent desired protein degradation and 0.1 mg/ml lysozyme to break the cell wall of 
the bacteria. Solution was sonicated for 5-6 cycles and centrifuged at 12,000 rpm for 20 minutes 
to spin down the inclusion body. Solution was resuspended in Triton Buffer (1% Triton and 2M 
urea in TE) centrifuged at 12,000 rpm for 20 minutes, pellet was retrieved, and step was repeated 
again. Solution was resuspended in 8 M guanidine hydrogen chloride and TE buffer. Solution 
was centrifuged at 12,000 rpm for 20 minutes and supernatant with crude protein was obtained. 
Protein Purification 
The proteins were purified first by the gel filtration method using size exclusion column 
(Hiload 26/30, Superdex 75 preparative grade ÄTKA prime) with washing solution of 50mM 
Tris, 5mM of EDTA, and 3M of Gu•HCl. And further purification was operated on HPLC by a 
gradient washout of 0.05% TFA in H2O and 0.05% TFA in CH3CN (340 µL TFA in 1L of 
distilled water). The HPLC products of protein was then placed in a dialysis cassette with 10,000 
molecular weight cutoff (MWCO) and allowed to undergo dialysis in two steps: first in buffer A 
of 25 mM formic acid to eliminate the acetonitrile and buffer B of 50 mM NaOAc to refold the 
protease.  
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Protein Crystallization 
The crystals of HIV-1 protease P51 and D25N mutant and TPV, SQV, DRV, and APV 
were grown using the hanging drop vapor diffusion procedure with a 1:20 and 1:40 ratio of 
inhibitor to protein. The hanging drop method entails the addition of a droplet (1 µL) of the 
purified protease and inhibitor complex, precipitant, buffer, and additives to a cover slip which is 
inverted onto a well with similar conditions. The drop is allowed to sit overnight at room 
temperature to allow for precipitation. The conditions under which these protein crystals were 
grown contain Potassium sodium tartrate, PEG 8000, HEPES, 0.1 M sodium cacodylate in 
different pH, 0.1 M ZnAc2 and 0.1 M CaAc2. Crystals were then frozen, mounted in 
cryptoprotector with 25% glycerol of the mother liquid, and sent for X-ray crystallography 
analysis at the Southeast Regional Collaborative Access Team X-ray beamlines of the Advanced 
Photon Source, Argonne National Laboratory, Argonne, IL.  
Measurement of Protease Activity and Inhibition 
The TPV inhibition constant for P51 was tried to be measured using a fluorescence assay 
with the substrate Abz-Thr-Ile-Nle-pNO2Phe-Gln-Arg-NH2 (where pNO2Phe is para-nitro-
phenylalanine, Nle is norleucine and Abz is anthranilic acid) (Bachem Bioscience Inc., King of 
Prussia, PA), which is based on the p2/NC cleavage site of the viral polyprotein. 10 μl PRP51 
with a concentration of about 50 μM with a gradient concentration of TPV was mixed with 100 
μl of reaction buffer [100 mM MES (4-morpholineethanesulfonic acid), pH 5.6, 400 mM NaCl, 1 
mM ethylenediaminetetraacetic acid, and 5% glycerol] at 26 ˚C. The reaction was initiated by 
adding substrate of a final concentration of 72 μM by monitoring the increase in fluorescence 
over 5 min using an excitation wavelength of 340 nm and emission wavelength of 420 nm 
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(pNO2Phe as quencher-fluorescent acceptor; Abz as fluorescent donor) with a POLARstar 
OPTIMA 96-well microplate instrument (BMC Labtech). 
 
Results 
Expression of HIV Protease P51 Mutant 
Expression had to be repeated since cells were not obtained during the first expression 
phase. When the cells were transferred to a larger broth, they double in number every 60 
minutes. Pellet was successfully centrifuged and approximately 3 grams of cells were grown.  
 
Purification of HIV Protease Mutant P51 
HIV PR p51 was purified using High Performance Liquid Chromatography (HPLC) and Gel 
Filtration (Figure . We obtained about 1.2 mg/ml for monomer. 
 
Crystallization of HIV Protease P51 Mutant with Inhibitors 
 Protein PR p51 D25N was used because the D25N mutation allowed for deactivation of 
protein activity. We did not try P51 without the D25N mutation. The concentration of protein 
that was used was 1.2 mg/ml. The protein crystals that were grown were PR p51 and TPV, PR 
p51 and APV, PR P51 and SQV, and PR p51 and DRV. In each condition, dH20 was added until 
final concentration of the mother liquid equaled 600 µl. One condition in which PR p51 and 
APV(protein-inhibitor ratio of 1:20) crystals grew were2M Potassium sodium (KNA)tartrate, 0.1 
Sodium cacodylate (NaCaco dylate) pH 6.6, HEPES,15% PEG 8000, 0.02M CaAc2, and dH2O. 
Another condition in which PR p51 and APV (ratio 1:20) crystals grew was 2M KNA tartrate,0.1 
M NaCaco dylate pH 6.0, HEPES, 20% PEG 8000, 0.02M CaAc2, and dH2O.The crystals were 
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medium sized in both conditions. For PR p51 and APV with a protein-inhibitor ratio of 1:40, one 
condition in which crystals grew was 2M KNA tartrate, 0.1 NaCaco dylate pH 6.6, 15% PEG 
8000, HEPES, 0.02 M CaAc2, and dH2O. Another condition in which crystals grew with PR p51 
and APV (ratio 1:40) was 2M KNA tartrate, 0.1 NaCaco dylate pH 6.0, 18% PEG 8000, HEPES, 
0.02 M CaAc2, and dH2O. For PR p51 and DRV (ratio 1:20), one condition in which crystals 
grew was 2M KNA tartrate, 0.1 M NaCaco dylate pH 6.6, HEPES, 15% PEG 8000, 0.02M 
ZnAc2, and dH2O (Image 1).The crystals that were grown were big in size. For PR p51 and SQV 
(ratio 1:20), one condition in which crystals grew was 2M KNA tartrate, 0.1 M NaCaco dylate 
pH 6.0, HEPES, 20% PEG 8000, 0.02M ZnAc2, and dH2O. Another condition in which PR p51 
and SQV (ratio 1:20) grew crystals was 2M KNA tartrate, 0.1 M NaCaco dylate pH 6.0, HEPES, 
10% PEG 8000, 0.02M CaAc2, and dH2O. When growing PR p51 and SQV (ratio 1:40) under 
the following conditions 2M KNA tartrate, 0.1 M NaCaco dylate pH 6.0, HEPES, 15% PEG 
8000, 0.02M ZnAc2, and dH2O, crystals grew. These crystals were medium sized. Lastly, for PR 
p51 and TPV, one condition in which crystals grew was 2M KNA tartrate, 0.1 M NaCaco dylate 
pH 6.0, HEPES, 20% PEG 8000, 0.02M ZnAc2, and dH2O (Image 2). Very small sized crystals 
formed. All crystals listed above were sent to Argonne National Laboratories for diffraction data 
collection at the Southeast Regional Collaborative Access Team X-ray beamlines. Processing 
and analysis of the X-ray crystallographic data is in progress.  
 
Enzyme activity and inhibition 
 The enzyme activity of the protease was tested and there was no activity. Inhibition of the 
enzyme could not be measured. The concentration used was 1.29 mg/ml. For inhibition constant 
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measurement, we did not obtain any result due the poor activity of P51. The protein did not show 
sufficient activity. The expression will need to be repeated with fresh cells and or plasmid DNA.  
 
Discussion 
 Antiviral drugs have been successful when it comes to reducing the effects of the HIV 
virus. With the development of drug resistance the virus continues to function and compromise 
the immune system of HIV/AIDS patients. HIV PR p51 (51 serial passages/ stages) was used in 
this study because it is one of many mutants that are extremely resistant to drug therapy for HIV. 
Studying HIV PR P51 in the complex with inhibitors can lead to the development of successful 
therapeutic agents. To analyze, the complex we expressed and purified the protein and grew 
crystals to get its crystalline structure. HIV PR P51 was expressed and purified successfully and 
protein crystals were grown of PR p51with 4 different inhibitors (TPV, SQV, DRV, and 
APV).PR p51 and TPV crystals were very small. PR p51 and SQV crystals were good medium 
sized crystals. PR p51 and APV crystals were also good medium sized crystals. PR p51 and 
DRV crystals were good and large in size. Enzyme activity and inhibition didn’t turn out as 
planned because the activity of p51 was poor. Therefore we could not measure the inhibition of 
the enzyme. The next step in research would be to redo the experiment with fresh cells or 
plasmid DNA to determine the inhibition constant measurement of the proteinP51. This research 
project is a portion of a bigger research project that is currently being conducted. The data 
obtained will help with the creation of new and successful antiviral drugs against HIV and it will 
also help better understand the mechanism and molecular origin of drug resistance. 
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Figure 7. This image represents the results we obtained from gel filtration. The high 
peak represents the purified protein PR p51 and D25N that we obtained. 
 
Figure 7. HIV-1 PR p51 Gel Filtration Results 
18 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 9. Picture of crystals grown for PR p51 and DRV (protein-inhibitor ratio 1:20). The 
conditions in which these crystals were grown are 2M KNA tartrate, 0.1 M NaCaco dylate pH 
6.6, HEPES, 15% PEG 8000, 0.02M ZnAc2, and dH2O. 
 
Figure 9. PR p51 with DRV crystals 
Figure 8. PR p51 and APV crystals. 
Figure 8. This image shows PR p51 and APV (protein-inhibitor ratio 1:20) crystals that grew 
under the following conditions: 2M KNA tartrate, 0.1 M NaCaco dylate pH 6.0, HEPES, 20% 
PEG 8000, 0.02M ZnAc2, and dH2O. 
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Figure 11. PR p51 and TPV crystals 
Figure 11. This photo represents PR p51 and TPV (ratio 1:20) crystals grown under the 
following conditions: 2M KNA tartrate, 0.1 M NaCaco dylate pH 6.0, HEPES, 20% 
PEG 8000, 0.02M ZnAc2, and dH2O. 
 
Figure 10. This figure represents crystals from PR p51 and SQV (ratio 1:20) which grew 
under the following conditions: 2M KNA tartrate, 0.1 M NaCaco dylate pH 6.0, HEPES, 10% 
PEG 8000, 0.02M CaAc2, and dH2O. 
 
Figure 10. PR p51 and SQV crystals. 
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